212 related articles for article (PubMed ID: 23276799)
1. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
Tanwar PS; Kaneko-Tarui T; Lee HJ; Zhang L; Teixeira JM
Carcinogenesis; 2013 Apr; 34(4):893-901. PubMed ID: 23276799
[TBL] [Abstract][Full Text] [Related]
2. A mouse model for endometrioid ovarian cancer arising from the distal oviduct.
van der Horst PH; van der Zee M; Heijmans-Antonissen C; Jia Y; DeMayo FJ; Lydon JP; van Deurzen CH; Ewing PC; Burger CW; Blok LJ
Int J Cancer; 2014 Sep; 135(5):1028-37. PubMed ID: 24474556
[TBL] [Abstract][Full Text] [Related]
3. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
4. Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.
Wu R; Zhai Y; Kuick R; Karnezis AN; Garcia P; Naseem A; Hu TC; Fearon ER; Cho KR
J Pathol; 2016 Nov; 240(3):341-351. PubMed ID: 27538791
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN.
Tanwar PS; Zhang L; Kaneko-Tarui T; Curley MD; Taketo MM; Rani P; Roberts DJ; Teixeira JM
PLoS One; 2011; 6(6):e20715. PubMed ID: 21695255
[TBL] [Abstract][Full Text] [Related]
6. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
7. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.
Zhai Y; Kuick R; Tipton C; Wu R; Sessine M; Wang Z; Baker SJ; Fearon ER; Cho KR
J Pathol; 2016 Jan; 238(1):21-30. PubMed ID: 26279473
[TBL] [Abstract][Full Text] [Related]
8. An in vivo model for the study of ovarian cancer and the persistence of characteristic mutations in xenografts.
Li Y; Gu YJ; Liu CN; Yue TF
Eur J Gynaecol Oncol; 2014; 35(4):387-92. PubMed ID: 25118479
[TBL] [Abstract][Full Text] [Related]
9. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
10. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
Hendrix ND; Wu R; Kuick R; Schwartz DR; Fearon ER; Cho KR
Cancer Res; 2006 Feb; 66(3):1354-62. PubMed ID: 16452189
[TBL] [Abstract][Full Text] [Related]
12. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis].
Castiblanco G A; Pires N Y; Wistuba O I; Riquelme S E; Andrade M L; Corvalán R A
Rev Med Chil; 2006 Mar; 134(3):271-8. PubMed ID: 16676097
[TBL] [Abstract][Full Text] [Related]
13. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
Yoshioka S; King ML; Ran S; Okuda H; MacLean JA; McAsey ME; Sugino N; Brard L; Watabe K; Hayashi K
Mol Cancer Res; 2012 Mar; 10(3):469-82. PubMed ID: 22232518
[TBL] [Abstract][Full Text] [Related]
14. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
15. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
17. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
[TBL] [Abstract][Full Text] [Related]
18. Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.
Matsumoto T; Yamazaki M; Takahashi H; Kajita S; Suzuki E; Tsuruta T; Saegusa M
Am J Clin Pathol; 2015 Sep; 144(3):452-63. PubMed ID: 26276776
[TBL] [Abstract][Full Text] [Related]
19. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
20. Endometriosis-associated Ovarian Cancers.
Anglesio MS; Yong PJ
Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
